Acepodia Biotech is a clinical-stage biotechnology company based in Alameda, CA, and Taipei City, Taiwan. They are dedicated to developing powerful and innovative cell therapies for patients with cancer, utilizing their unique Antibody-Cell Conjugation (ACC) platform technology. Their ACC technology allows for the attachment of tumor-targeting antibodies directly to immune cells, enhancing the potency and specificity of cell therapies without the need for genetic engineering.
Acepodia's cell therapies include ACC 2 T Cells, which elicit a robust anticancer immune response, and oNK Cells, which are amplified natural killer cells with enhanced cancer-killing potential. Their goal is to provide highly effective and accessible treatments for a wide range of hematologic and solid tumor cancers. With a focus on advancing the next generation of immunotherapy, Acepodia is at the forefront of transforming cancer treatment.
Generated from the website